Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,958.40
(
-0.24%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.80
(
2.54%
)
Bitcoin
74,011.97
(
-1.11%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 92044

Monday, 05/24/2010 8:45:35 AM

Monday, May 24, 2010 8:45:35 AM

Post# of 257250
ABT received a $30M milestone payment from BIIB for enrollment of the first patient in the phase-3 daclizumab trial in RRMS:

http://finance.yahoo.com/news/Biogen-Idec-and-Abbott-bw-4069182014.html?x=0&.v=1


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now